Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the phase 2 FREEDOM-3 trial and preclinical studies of the cell therapy FCR-001.
Scott Requadt
Advertisement
Chief executive officer, Talaris Therapeutics
Articles by Scott Requadt
Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the long-term follow-up and FREEDOM-1 trials of FCR-001.
Scott Requadt, chief executive officer, Talaris Therapeutics, discussed the company’s goal to reprogram the immune system.
Advertisement
Latest Updated Articles
Reprogramming the Immune System for Kidney Transplant and SclerodermaPublished: December 6th 2021 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
CGTLive®’s Weekly Rewind – October 24, 2025
2
Guess the Therapy Answer October 23, 2025
3
CARsgen’s CAR-T Satri-Cel Significantly Reduces CA19-9 Levels in Patients With Pancreatic Ductal Adenocarcinoma
4
